Evidence map›Paper›PMID 27489357›Full record

ArticleOncotarget2016

Increased frequency of circulating Th22 cells in patients with B-cell non-Hodgkin's lymphoma.

Ting Lu, Yan Liu, Shuang Yu, Congcong Yin, Peng Li, Jingjing Ye, Daoxin Ma, Chunyan Ji

Open access · diamondAbstract read
In one paragraph

Article in Oncotarget, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
0.7field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 13 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. The role of IL-22 in cancer.Medical oncology (Northwood, London, England) · 2024
    Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Ting LuDepartment of Hematology, Qilu Hospital, Shandong University, Jinan, PR China.
Yan LiuDepartment of Hematology, Qilu Hospital, Shandong University, Jinan, PR China.
Shuang YuDepartment of Hematology, Qilu Hospital, Shandong University, Jinan, PR China.
Congcong YinDepartment of Hematology, Qilu Hospital, Shandong University, Jinan, PR China.
Peng LiDepartment of Hematology, Qilu Hospital, Shandong University, Jinan, PR China.
Jingjing YeDepartment of Hematology, Qilu Hospital, Shandong University, Jinan, PR China.
Daoxin MaDepartment of Hematology, Qilu Hospital, Shandong University, Jinan, PR China.
Chunyan JiDepartment of Hematology, Qilu Hospital, Shandong University, Jinan, PR China.
Qilu Hospital of Shandong University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

T helper (Th) 22 cells play important roles in the pathogenesis of autoimmune and inflammatory diseases, and their function in tumors remains uncertain. In the current study, we investigated the alternations and clinical significance of circulating Th22 cells in patients with B-cell non-Hodgkin's lymphoma (B-NHL). We found that the frequency of Th22 cells was significantly elevated in peripheral blood of newly-diagnosed B-NHL patients, and returned to normal level after chemotherapy. In consistent with increased Th22 frequency, plasma IL-22 and IL-6 levels in B-NHL patients were remarkably increased. Moreover, the increased Th22 frequency was associated with the older age (> 60 yr) and a poorer response to therapy in B-NHL patients. In addition, there existed a statistically positive correlation between circulating Th22 and Th17 frequencies in B-NHL patients. Our data demonstrated that circulating Th22 frequency was associated with the clinical outcome and prognosis of B-NHL patients, indicating that Th22 immune response might play an important role in the development and progression of B-NHL.

Indexed as

AdultAgedB-LymphocytesCase-Control StudiesFemaleHumansInflammationInterleukin-22Interleukin-6InterleukinsLymphoma, B-CellLymphoma, Non-HodgkinMaleMiddle AgedNeoplastic Cells, CirculatingPrognosisIL6 protein, humanInterleukin-22Interleukin-6InterleukinsTumor Necrosis Factor-alphaB-cell non-Hodgkin’s lymphomaIL-22prognosisTh22

Identifiers

PMID27489357
PMCPMC5302935
OpenAlexW2501723733

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.